查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2001046

mRNA治疗市场：依技术平台、递送方式及治疗应用划分－2026-2032年全球市场预测

mRNA Therapeutics Market by Technology Platform, Delivery Method, Therapeutic Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，mRNA 疗法市值将达到 113.3 亿美元，到 2026 年将成长至 125.8 亿美元，到 2032 年将达到 270.5 亿美元，复合年增长率为 13.23%。

主要市场统计数据
基准年 2025 113.3亿美元
预计年份：2026年 125.8亿美元
预测年份 2032 270.5亿美元
复合年增长率 (%) 13.23%

科学突破、对扩大生产规模的需求以及监管趋势相互交织，标誌着 mRNA 治疗领域的关键转折点，迫使人们重新调整研发重点。

mRNA疗法领域目前正处于科学检验、规模化生产和法规结构演变的三重交汇点，这为研发人员、投资者和卫生监管机构创造了一个独特的转折点。核心平台技术的进步表明，编码递送治疗有效载荷可以触发持续且可控的生物反应。同时，製剂科学和低温运输物流的同步改进正在降低临床应用的传统障碍。随着计划从概念验证（PoC）阶段进入后期开发阶段，相关人员面临着日益复杂的决策，涵盖从平台选择和给药途径到特定治疗方法的安全性等诸多方面。

平台成熟、製造现代化、监管协调和递送途径优化正在共同改变 mRNA 疗法的临床和商业策略。

近年来，变革性的变化重新定义了mRNA疗法的研发、生产和应用。平台演进是其中最重要的变革之一，脂质体化学和新型载体系统的最佳化显着改善了体内分布和耐受性。这项进步拓展了mRNA疗法的治疗范围，使其不再局限于疫苗应用，而是涵盖了慢性病和罕见疾病。同时，生产技术的进步——例如连续生产流程、一次性使用系统和模组化设施设计——缩短了製程转移前置作业时间，并提高了多产品生产工厂的柔软性。这些营运方面的改进降低了临床批次规模化的门槛，并支援更有效率的产品开发週期。

2025 年美国关税政策的变化将如何影响 mRNA 疗法开发中的供应链结构、筹资策略和製造地决策？

2025年美国关税政策发展的累积影响将为mRNA疗法供应链中的企业带来一系列营运和策略的考量。关税变化正在影响关键上游工程原材料（尤其是脂质、核苷酸和特殊添加剂）的筹资策略，迫使各团队重新评估供应商所在地和库存缓衝。为此，许多企业开始实现供应商多元化，以减少对单一国家的依赖；而另一些企业则加快对贸易协定更为有利地区的替代供应商进行认证。这些措施正在重塑采购计划，并增加供应商审核和品管的复杂性。

策略性細項分析揭示了平台选择、治疗标靶优先排序和交付模式如何共同决定开发路径和营运需求。

对细分市场动态的深入分析揭示了平台选择、治疗标靶和递送方法之间的相互作用，从而定义了专案层面的策略和商业化路径。在考虑技术平台差异化时，脂质奈米颗粒正逐渐成为一种用途广泛且应用广泛的载体系统，能够支援全身和局部递送目标。基于聚合物的平台因其可调控的释放动力学和模组化化学结构而备受关注，这些特性可以解决稳定性方面的限制。病毒载体在需要高转导效率的应用中仍被广泛研究，尤其是在需要长期表达或细胞特异性靶向的情况下。这些平台选择促使申办方将平台选择与生物学作用机制和生产能力相匹配。

世界各地区域政策、製造业生态系统和法规的多样性决定了发展和供应连续性策略的顺序。

区域趋势在整个mRNA治疗领域对研发重点、监管路径和商业化策略的製定起着决定性作用。在美洲，市场相关人员必须有效利用一个以完善的临床网络、活跃的创业投资和私募股权活动以及不断完善指导方针以适应平台型应用为特征的生态系统。这些特点为后期临床试验和合作创造了有利条件，从而可以加速临床检验并加快与支付方的谈判。该地区还拥有一个成熟的契约製造和开发服务（CMOD）生态系统，为申办方提供了多种无需立即进行资本密集型设施扩建即可扩大生产规模的途径。

竞争格局显示，创新主导合作关係、製造领域的垂直整合以及加速从实验室向临床实践过渡的策略伙伴关係正在形成。

mRNA疗法领域的竞争格局呈现出科学差异化、合作模式和垂直整合策略交织的态势。创新公司优先考虑平台新颖性和临床差异化，以确保获得利润丰厚的合作关係和许可协议；而成熟的生物製药公司则通常透过收购和策略合作，快速获取尖端技术平台。合约研发生产机构（CDMO）正积极应对这项挑战，拓展其在製剂、无菌填充和包装以及低温运输物流等方面的能力，从而成为支持临床项目拓展和商业化推出的重要合作伙伴。

为高阶主管提供实际有效的建议，以加快研发进度、增强供应连续性，并使证据产生与支付方的期望保持一致。

产业领导企业可以采取一系列切实可行的措施，在应对技术复杂性和商业性不确定性的同时，加速专案成功。透过优先考虑平台无关的开发路径，企业可以在分析、对比试验和监管沟通方面实现跨专案的效率提升。早期投资于製剂和剂量优化可以降低后续临床风险，并提高患者接受度，尤其是在需要重复给药的适应症。企业还应将供应连续性计划纳入其开发计划，在关键试验开始前儘早检验替代供应商和应急生产安排。这有助于减轻贸易和物流中断对营运的影响。

透过结合专家访谈、监管审查、技术文献整合和情境分析等严谨且多方面的研究途径，提取出可操作的产业见解。

本分析的研究基础包括定性专家访谈、对公开监管文件的审查以及对近期科学文献的跨学科整合，旨在全面了解mRNA治疗生态系统。透过与科学家、製程工程师、监管顾问、生产主管和商业负责人的对话，我们掌握了实际情况并确定了新兴的最佳实践。我们也仔细审查了监管文件和指导资料，以获得符合当前平台申报和比较生产评估要求的见解。此外，我们也查阅了科学论文和会议论文集，以了解载体化学、给药途径和製剂稳定性数据的最新进展。

科学、营运和政策趋势的最终整合将决定哪些组织能够将 mRNA 创新转化为可持续的临床和商业性成功。

mRNA疗法领域的特点是技术快速发展、营运模式不断转变以及政策环境日新月异，这些因素共同带来了巨大的机会和复杂的挑战。载体技术的进步、生产製造的现代化以及递送途径的优化，拓展了mRNA疗法的应用范围，而监管和贸易趋势则要求企业进行更精细的风险管理和策略规划。在这种环境下，能够将卓越的科学研究能力与切实可行的供应链设计、稳健的监管策略以及与早期支付方的合作相结合的企业，更有可能取得成功。将敏捷的创新者与成熟的生产或商业化合作伙伴联繫起来的协作模式，有望加速mRNA实用化的推广应用并降低实施风险。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 依技术平台分類的mRNA治疗药物市场

  • 脂质奈米颗粒
  • 聚合物基
  • 病毒载体

第九章 mRNA治疗药物市场：依给药方式划分

  • 肌肉内部
  • 静脉
  • 皮下

第十章：依治疗应用分類的mRNA治疗药物市场

  • 循环系统
  • 感染疾病
  • 肿瘤学
  • 罕见疾病

第十一章 mRNA治疗药物市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十二章 mRNA 治疗药物市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十三章 mRNA治疗药物市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十四章：美国mRNA治疗药物市场

第十五章：中国的mRNA治疗市场

第十六章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Altamira Therapeutics, Inc.
  • Arcturus Therapeutics Holdings, Inc.
  • AstraZeneca plcEthris GmbH
  • BioNTech SE
  • Chimeron Bio, Inc.
  • CureVac NV
  • eTheRNA Immunotherapies NV
  • Genevant Sciences Corporation
  • GlaxoSmithKline plc
  • Gritstone Bio, Inc.
  • Immorna Biotherapeutics, Inc.
  • Kernel Biologics, Inc.
  • Lonza Group Ltd.
  • Merck & Co., Inc.
  • Moderna, Inc.
  • MycoTechnology, Inc.
  • NobleGen, Inc.
  • Novartis AG
  • Nutcracker Therapeutics, Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Strand Therapeutics, Inc.
  • Tiba Biotech, LLC
  • VaxEquity Ltd.
Product Code: MRR-205091A88BBD

The mRNA Therapeutics Market was valued at USD 11.33 billion in 2025 and is projected to grow to USD 12.58 billion in 2026, with a CAGR of 13.23%, reaching USD 27.05 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 11.33 billion
Estimated Year [2026] USD 12.58 billion
Forecast Year [2032] USD 27.05 billion
CAGR (%) 13.23%

A critical juncture in mRNA therapeutics where scientific breakthroughs, manufacturing scale demands, and regulatory developments converge to reshape development priorities

The field of mRNA therapeutics is now at the intersection of scientific validation, manufacturing scale-up, and evolving regulatory frameworks, creating a unique inflection point for developers, investors, and health authorities. Advances in core platform technologies have demonstrated that encoded delivery of therapeutic payloads can trigger durable and controllable biological responses, while parallel improvements in formulation science and cold-chain logistics have reduced historical barriers to clinical translation. As projects move from proof-of-concept to later-stage development, stakeholders face an increasingly complex set of decisions spanning platform selection, delivery routes, and therapy-specific safety profiles.

Against this backdrop, the industry must reconcile rapid technological progress with the practicalities of commercial execution. Investment priorities are shifting from purely discovery-focused activities to buildouts in manufacturing capacity, quality assurance, and regulatory readiness. Meanwhile, cross-disciplinary collaboration between immunologists, formulation scientists, and process engineers is becoming essential to accelerate timelines and mitigate clinical risk. The introduction of new regulatory guidances and payer discussions further underscores the need for integrated strategies that combine scientific rigor with pragmatic commercialization planning. Ultimately, the current environment rewards organizations that can translate technical differentiation into reproducible clinical outcomes and sustainable supply chains.

Platform maturation, manufacturing modernization, regulatory harmonization, and delivery route optimization are collectively remaking clinical and commercial strategies in mRNA therapeutics

Recent years have witnessed transformative shifts that are redefining how mRNA therapeutics are developed, manufactured, and delivered. Platform evolution is one of the most consequential shifts, as optimizations in lipid nanoparticle chemistry and alternative carrier systems have materially improved biodistribution and tolerability profiles. This progress has, in turn, enabled broader therapeutic ambitions beyond vaccine applications into chronic and rare disease indications. Simultaneously, advances in manufacturing technologies-continuous processing, single-use systems, and modular facility designs-have reduced lead times for process transfer and increased flexibility for multi-product plants. These operational improvements lower the threshold for scaling clinical batches and support more iterative product development cycles.

Regulatory pathways are also evolving from ad hoc, indication-specific guidance toward more standardized frameworks that recognize platform-based similarities. These regulatory trends are encouraging sponsors to design development programs that leverage platform data packages to streamline subsequent product filings. Another major shift is the growing emphasis on delivery modality; intramuscular, intravenous, and subcutaneous routes are now being optimized in parallel for distinct therapeutic goals, which has implications for formulation, dosing strategies, and patient-centric considerations. Finally, commercial models are adapting to a landscape where partnerships between small innovators and large-scale manufacturers are increasingly commonplace, enabling nimble science to access the production capacity and market access expertise necessary for broader patient reach.

How recent United States tariff shifts in 2025 are reshaping supply chain architecture, procurement strategies, and manufacturing footprint decisions across mRNA therapeutic development

The cumulative impact of the United States tariff policy developments in 2025 introduces a series of operational and strategic considerations for organizations involved in the mRNA therapeutics supply chain. Tariff changes have influenced sourcing strategies for key upstream inputs, particularly lipids, nucleotides, and specialized excipients, causing teams to re-evaluate supplier footprints and inventory buffers. In response, many organizations have initiated supplier diversification efforts to reduce single-country exposure, while others have accelerated qualification of alternative vendors in jurisdictions with more favorable trade arrangements. These efforts are reshaping procurement timelines and adding complexity to supplier audits and quality oversight.

Logistics and manufacturing economics have also been affected, as changes in import duties alter landed costs for critical components and finished goods. The result is a recalibration of near-term procurement priorities, with increased emphasis on long-lead contracts and strategic stockpiling for materials that are both specialized and supply-constrained. Companies are also reassessing their manufacturing footprints, weighing the costs and regulatory time associated with relocating or expanding production capacity in multiple trade zones. In parallel, manufacturers are rethinking contracting strategies, including longer-term service agreements with contract development and manufacturing organizations to lock in capacity and mitigate the operational variability introduced by shifting tariff regimes.

Finally, the tariff environment has underscored the importance of policy intelligence as part of commercial planning. Development teams and business leaders are collaborating more closely with trade and legal experts to model scenario impacts on cost structures and timelines. This alignment is prompting organizations to incorporate tariff sensitivity analyses into their go-to-market and supply continuity plans, ensuring that development milestones remain resilient to external trade policy changes.

Strategic segmentation analysis revealing how platform choices, therapeutic target priorities, and delivery modalities jointly determine development paths and operational needs

Insight into segmentation dynamics reveals how platform choices, therapeutic targets, and delivery methods interact to define program-level strategies and commercial pathways. When considering technology platform differentiation, lipid nanoparticles have emerged as a versatile and widely adopted carrier system that supports systemic and local delivery ambitions; polymer-based platforms are attracting interest for tailored release kinetics and modular chemistry that can address stability constraints; viral vectors continue to be explored for applications where high transduction efficiency is essential, particularly when long-term expression or cell-specific targeting is required. Together, these platform options compel sponsors to align platform selection with the biological mechanism of action and manufacturing capabilities.

Therapeutic application segmentation further refines strategic choices. For cardiovascular indications, developers prioritize delivery routes and formulation stability that optimize tissue targeting and repeat dosing tolerability. In infectious diseases, development pathways often emphasize immunogenicity profiles and rapid scalability to address outbreak scenarios. Oncology programs center on tumor targeting, dosing intensity, and combination strategies with existing modalities, while rare diseases frequently demand bespoke development plans that emphasize small-batch manufacturing, high-potency formulation, and patient-centered administration modalities. These therapeutic distinctions drive different risk tolerances, clinical trial designs, and commercialization partners.

Delivery method segmentation is equally consequential, as intramuscular administration supports decentralized delivery and broad immunization campaigns, intravenous approaches enable systemic biodistribution for complex indications, and subcutaneous routes offer patient-friendly dosing possibilities for chronic therapies. Selecting the appropriate delivery modality requires integrating clinical goals, patient experience considerations, and supply-chain realities, since each route carries distinct formulation and stability requirements. The interplay among platform, application, and delivery modality shapes program timelines, clinical endpoint selection, and the types of manufacturing competencies required to execute reliably.

Regional policy, manufacturing ecosystems, and regulatory variability across global territories that shape development sequencing and supply continuity strategies

Regional dynamics play a decisive role in shaping R&D priorities, regulatory pathways, and commercialization strategies across the mRNA therapeutics landscape. In the Americas, market actors must navigate an ecosystem characterized by advanced clinical networks, strong venture and private-equity activity, and regulatory agencies that are refining guidance to accommodate platform-based submissions. These features create fertile ground for late-stage trials and partnerships that can accelerate clinical validation and payer discussions. The region also features a dense contract manufacturing and development services ecosystem, offering sponsors multiple pathways to scale production without immediate capital-intensive facility expansion.

In Europe, Middle East & Africa, regulatory heterogeneity across jurisdictions and the presence of regional health technology assessment frameworks influence go-to-market sequencing and evidence generation priorities. Companies operating in this region often map clinical programs to achieve both centralized regulatory filings where appropriate and tailored national strategies to address reimbursement nuances. Additionally, the region presents collaboration opportunities with academic centers and consortiums that can support translational research and comparative effectiveness studies. In Asia-Pacific, diverse market dynamics include strong government-led manufacturing initiatives, rapidly scaling clinical trial capacity, and interest in domesticizing biomanufacturing capabilities. Policymakers across these markets are increasingly supportive of biotech and advanced therapy investments, creating incentives for local production and regionally focused supply chain strategies.

Across all regions, cross-border collaboration remains a key enabler for advancing complex programs. Regulatory dialogue, manufacturing partnerships, and clinical site networks that span multiple geographies are instrumental for accelerating development timelines and ensuring supply continuity. Effective regional strategies therefore balance global platform validation with locally tailored regulatory and commercial approaches.

Competitive patterns showing innovation-led alliances, vertical integration in manufacturing, and strategic partnerships that accelerate translation from lab to clinic

Competitive behavior in the mRNA therapeutics space reflects a mix of scientific differentiation, partnership models, and vertical integration strategies. Innovators prioritize platform novelty and clinical differentiation to secure advantageous partnering or licensing agreements, while established biopharma players typically pursue acquisition or strategic collaboration to gain rapid access to leading technology platforms. Contract development and manufacturing organizations are responding by expanding capabilities across formulation, aseptic fill-finish, and cold-chain logistics, positioning themselves as essential partners for scaling clinical programs and supporting commercial launches.

Across corporate portfolios, several recurring strategic patterns emerge. First, companies with strong platform IP and robust preclinical evidence are leveraging selective alliances to accelerate translational activities without relinquishing long-term value. Second, organizations focused on chronic disease applications are investing in delivery and formulation differentiation to enable repeated dosing and improve patient adherence. Third, firms targeting oncology and rare disease programs are building close relationships with specialized clinical networks and patient advocacy groups to inform trial design and accelerate enrollment. Finally, manufacturing-focused firms and service providers are carving out competitive moats by offering integrated end-to-end solutions, creating value propositions that reduce the coordination burden for sponsors and compressed timelines for production scale-up.

Practical, high-impact recommendations for executives to accelerate development timelines, strengthen supply continuity, and align evidence generation with payer expectations

Industry leaders can adopt a set of actionable practices to navigate technological complexity and commercial uncertainty while accelerating program success. Prioritizing platform-agnostic development pathways allows organizations to capture cross-program efficiencies in analytics, comparability studies, and regulatory engagements. Investing early in formulation and delivery optimization reduces downstream clinical risk and improves patient acceptability, particularly for indications that require repeat dosing. Companies should also embed supply continuity planning into their development timelines, validating secondary suppliers and contingency manufacturing arrangements well before pivotal studies begin, which mitigates the operational impact of trade or logistics disruptions.

From a go-to-market perspective, establishing strategic partnerships with contract manufacturers and clinical networks can unlock capacity and expedite enrollment without large upfront capital commitments. Leaders should also institutionalize regulatory intelligence functions to track evolving guidances and create modular dossier elements that can be repurposed across indications. Commercial teams must engage with payers and health technology assessors early to shape evidence generation strategies that demonstrate value beyond traditional clinical endpoints. Finally, cultivating cross-functional governance that aligns R&D, manufacturing, regulatory affairs, and commercial planning will accelerate decision-making and ensure that scientific advances translate into executable launch plans and sustainable product lifecycles.

A rigorous, multi-source research approach combining expert interviews, regulatory review, technical literature synthesis, and scenario analysis to surface actionable industry insights

The research underpinning this analysis combined qualitative expert interviews, public regulatory documentation reviews, and cross-disciplinary synthesis of recent scientific literature to ensure a comprehensive view of the mRNA therapeutics ecosystem. Expert conversations were conducted with scientists, process engineers, regulatory advisors, manufacturing executives, and commercial strategists to capture operational realities and identify emergent best practices. Regulatory source materials and guidance documents were examined to align insights with current expectations for platform-based submissions and manufacturing comparability assessments. Scientific publications and conference proceedings were reviewed to capture the latest advances in carrier chemistry, delivery routes, and formulation stability data.

The methodology emphasized triangulation: qualitative inputs were cross-validated against contemporaneous policy shifts and technical publications to reduce bias and surface robust trends. Case-level analyses of representative development programs provided granularity on how platform choice, delivery route, and therapeutic target drive different risk and operational profiles. Supply chain scenario planning and tariff sensitivity reviews were integrated to assess how external policy and logistics factors influence program viability. Throughout, the approach prioritized actionable insights relevant to decision-makers, focusing on practical implications for clinical design, manufacturing strategy, regulatory interactions, and commercial planning.

Final synthesis of scientific, operational, and policy dynamics that determine which organizations will convert mRNA innovation into durable clinical and commercial success

The mRNA therapeutics landscape is characterized by rapid technical progress, shifting operational paradigms, and evolving policy environments that together present both significant opportunities and complex challenges. Progress in carrier technologies, manufacturing modernization, and delivery route optimization has expanded the range of feasible therapeutic applications, while regulatory and trade developments require more sophisticated risk management and strategic planning. Success in this environment will favor organizations that integrate scientific excellence with pragmatic supply chain design, robust regulatory strategies, and early payer engagement. Collaborative approaches that pair nimble innovators with established manufacturing or commercialization partners are likely to accelerate translation and reduce executional risk.

In conclusion, the path forward requires a balanced approach that aligns platform and delivery selection with clinical objectives, anticipates supply and policy headwinds, and builds cross-functional capabilities to translate insights into deliverable programs. Organizations that proactively address these dimensions will be better positioned to convert scientific promise into durable therapeutic and commercial outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. mRNA Therapeutics Market, by Technology Platform

  • 8.1. Lipid Nanoparticles
  • 8.2. Polymer Based
  • 8.3. Viral Vectors

9. mRNA Therapeutics Market, by Delivery Method

  • 9.1. Intramuscular
  • 9.2. Intravenous
  • 9.3. Subcutaneous

10. mRNA Therapeutics Market, by Therapeutic Application

  • 10.1. Cardiovascular
  • 10.2. Infectious Diseases
  • 10.3. Oncology
  • 10.4. Rare Diseases

11. mRNA Therapeutics Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. mRNA Therapeutics Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. mRNA Therapeutics Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States mRNA Therapeutics Market

15. China mRNA Therapeutics Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. Altamira Therapeutics, Inc.
  • 16.6. Arcturus Therapeutics Holdings, Inc.
  • 16.7. AstraZeneca plcEthris GmbH
  • 16.8. BioNTech SE
  • 16.9. Chimeron Bio, Inc.
  • 16.10. CureVac N.V.
  • 16.11. eTheRNA Immunotherapies N.V.
  • 16.12. Genevant Sciences Corporation
  • 16.13. GlaxoSmithKline plc
  • 16.14. Gritstone Bio, Inc.
  • 16.15. Immorna Biotherapeutics, Inc.
  • 16.16. Kernel Biologics, Inc.
  • 16.17. Lonza Group Ltd.
  • 16.18. Merck & Co., Inc.
  • 16.19. Moderna, Inc.
  • 16.20. MycoTechnology, Inc.
  • 16.21. NobleGen, Inc.
  • 16.22. Novartis AG
  • 16.23. Nutcracker Therapeutics, Inc.
  • 16.24. Pfizer Inc.
  • 16.25. Sanofi S.A.
  • 16.26. Strand Therapeutics, Inc.
  • 16.27. Tiba Biotech, LLC
  • 16.28. VaxEquity Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MRNA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MRNA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MRNA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA MRNA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MRNA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY LIPID NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY LIPID NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY POLYMER BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY POLYMER BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY POLYMER BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY VIRAL VECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY VIRAL VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. AMERICAS MRNA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 37. AMERICAS MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 38. AMERICAS MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 39. AMERICAS MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 40. NORTH AMERICA MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. NORTH AMERICA MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 42. NORTH AMERICA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 43. NORTH AMERICA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 44. LATIN AMERICA MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. LATIN AMERICA MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 46. LATIN AMERICA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 47. LATIN AMERICA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 48. EUROPE, MIDDLE EAST & AFRICA MRNA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 49. EUROPE, MIDDLE EAST & AFRICA MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 50. EUROPE, MIDDLE EAST & AFRICA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 51. EUROPE, MIDDLE EAST & AFRICA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 52. EUROPE MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. EUROPE MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 54. EUROPE MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 55. EUROPE MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 56. MIDDLE EAST MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. MIDDLE EAST MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 58. MIDDLE EAST MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 59. MIDDLE EAST MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 60. AFRICA MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. AFRICA MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 62. AFRICA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 63. AFRICA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. ASEAN MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. ASEAN MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 71. ASEAN MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 72. ASEAN MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 73. GCC MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GCC MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 75. GCC MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 76. GCC MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPEAN UNION MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPEAN UNION MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPEAN UNION MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPEAN UNION MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 81. BRICS MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. BRICS MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 83. BRICS MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 84. BRICS MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 85. G7 MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. G7 MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 87. G7 MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 88. G7 MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 89. NATO MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. NATO MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 91. NATO MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 92. NATO MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 95. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 96. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 97. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 98. CHINA MRNA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 99. CHINA MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 100. CHINA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 101. CHINA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)